Company Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States.

The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.

It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

Country	United States
Founded	1996
IPO Date	Jun 5, 2001
Industry	Biotechnology
Sector	Healthcare
Employees	29
CEO	Rostislav Raykov

Contact Details

Address: Po Box 13628, 68 Tw Alexander Drive Research Triangle Park, North Carolina 27709 United States
Phone	(919) 636-4530
Website	fennecpharma.com

Stock Details

Ticker Symbol	FENC
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001211583
CUSIP Number	31447P100
ISIN Number	CA31447P1009
SIC Code	2836

Key Executives

Name	Position
Rostislav Raykov	Chief Executive Officer and Director
Robert C. Andrade	Chief Financial Officer
Adrian J. Haigh	Chief Operating Officer
Mark Gowland	Controller
Lei Fang	President of Pharstat Inc

Latest SEC Filings

Date	Type	Title
Jul 2, 2024	144	Filing
Jul 2, 2024	8-K	Current Report
Jun 27, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals
Jun 25, 2024	8-K	Current Report
Jun 3, 2024	144	Filing
May 14, 2024	10-Q	Quarterly Report
May 13, 2024	DEF 14A	Other definitive proxy statements
May 9, 2024	8-K	Current Report
May 1, 2024	144	Filing
Apr 22, 2024	144	Filing

View All SEC Filings